We are live on
!
Find out more
FM
Frazier Management Portfolio holdings
AUM
$1.12M
1-Year Est. Return
151.58%
This Fund
S&P 500
This Quarter
Est. Return
+5.06%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$239M
AUM Growth
–
Cap. Flow
+$221M
Cap. Flow
% of AUM
92.59%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
7
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Glaukos
GKOS
|
+$59.7M |
| 2 |
Collegium Pharmaceutical
COLL
|
+$39.6M |
| 3 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
+$37M |
| 4 |
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
|
+$27.7M |
| 5 |
FOLD
Amicus Therapeutics
FOLD
|
+$26.3M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
ACMV
FRCMI
DB
NAM
AP
ID
CI
DIF
Frazier Management's Q4 2015 Portfolio in Review
Q4 2015 is the first quarter with a 13F filing on record for Frazier Management, which disclosed 7 positions worth $239M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Glaukos: 2,603,362 shares worth $64.3M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Frazier Management's largest Q4 2015 buy was Glaukos: 2,603,362 shares worth $64.3M.
- Frazier Management's ten largest holdings make up 100% of its $239M portfolio in Q4 2015.
- Frazier Management disclosed 7 positions in Q4 2015, its first 13F filing on record.
Based on Frazier Management's 13F filing for Q4 2015, filed 11 Feb 2016.